Event List

Home > Event List

NSW/ACT Branch Free Webinars: The Liver Ablative Radiotherapy with KIM (LARK) trial


Date(s):
21st Jul 2020
Time:
1:00PM - 2:00PM
Venue:
Webinar Link will be sent to you after you register for this event.

Costs:

Non-Members: Free
Members: Free

Members, login now to receive your best price
Description:

FREE - ACPSEM NSW/ACT Branch Free Webinar Series: The Liver Ablative Radiotherapy with KIM (LARK) trial

ACPSEM NSW/ACT Branch has organised a free webinar for all members of the College. 
Please feel free to invite anyone who would benefit from these webinars.  As numbers are limited to 500, a zoom link will be sent to those who are registered for this webinar. These webinars are interactive and all questions and comments are welcome.

Topic:   

The webinar session will be chaired by Zoë Moutrie
Talk 1: Democratising real-time image guided radiation therapy: Initial findings from the TROG 17.03 Liver Ablative Radiotherapy with KIM (LARK) trial-- Presented by Paul Keall 
Talk 2: The LARK trial liver SABR planning challenge -- Presented by Trevor Ackerly 

Kilovoltage intrafraction monitoring, or KIM, is a real-time image-guidance radiation therapy (IGRT) system that has been integrated with conventional linear accelerators. KIM provides tumour translation and rotation (6 degree of freedom) target motion information. KIM is a software device that converts conventional radiation therapy systems into real-time IGRT systems, thereby potentially democratising real-time IGRT by enabling broad access to this technology.  KIM has been used to treat over 120 prostate cancer patients with over 2000 individual treatment fractions. Until recently, KIM had only been used for prostate cancer treatment.

Motion management is important for prostate cancer radiation therapy, however it is even more important for liver cancer ablative radiation therapy. This need sparked the development of the Cancer Australia-funded TROG 17.03 Liver Ablative Radiotherapy with KIM (LARK) trial. The LARK trial will test the hypothesis that the incorporation of KIM in liver SABR improves cancer targeting accuracy, patient treatment outcomes, and treatment efficiency. The first LARK trial patient was treated at the Crown Princess Mary Cancer Centre at Westmead Hospital in January 2020.  The rationale, trial details, initial findings and future directions of the LARK trial and the KIM technology will be discussed by Paul, followed by a discussion of the LARK planning challenge by Trevor.

CPD: 

2 CPD Points will be automatically allocated to medical physicists who register and attend this webinar and automatically recorded in their CPD Tracker.   If you are watching this webinar as a group, we strongly recommend that everyone of the group should register for this webinar individually.  Otherwise only those who are registered for this webinar will be allocated for CPD points.  Our Office will cross-check the attendance with the registered delegates' names and allocate CPD points. Therefore please enter your full name (s) when you login to the webinar. 

Ref: COUR-P0000008-2

Default